TheFly.com ATNM $25 TARGET
TODAY, NOVEMBER 05, 2020
ATNM
08:55
Rec-Initiate
Actinium Pharmaceuticals initiated with a Buy at Alliance Global Partners
Alliance Global Partners analyst Matt Cross initiated coverage of Actinium Pharmaceuticals with a Buy rating and $25 price target.
Related articles
YESTERDAY, NOVEMBER 04, 2020
ATNM
12:23
Hot Stocks
Actinium reports 100% remission rate in third dose cohort of Phase 1 trial
Actinium Pharmaceuticals announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin achieved remission. Across all three cohorts, 67% or 10/15 patients treated with 0.25, 0.50 and 0.75 uCi/kg of Actimab-A and the standard regimen of CLAG-M achieved a Complete Remission or Complete Remission with inadequate hematopoietic recovery. Further, 83% of patients who received 3 or fewer prior lines of treatment achieved CR or CRi. Notably, 70% of CR/CRi patients were MRD negative indicating a deep remission with no detectable disease. These results which include subtherapeutic doses of Actimab-A in the first two dose cohorts and represent a marked improvement over CLAG-M treatment alone implying potential mechanistic synergy. This novel Phase 1 combination trial is for patients with relapsed or refractory acute myeloid leukemia age 18 and above deemed medically fit for cytotoxic chemotherapy. This data has been accepted for oral presentation at the 2020 American Society of Hematology annual meeting that is being he
